

YZATIS - Evaluation et évolution de la prise en charge thérapeutique à moyen terme des patients séropositifs pour le VIH-1 traités avec une combinaison antirétrovirale incluant Atazanavir

Head :Bennai Yacia, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Last update : 09/05/2017 | Version : 1 | ID : 128

General	
Identification	
Detailed name	Evaluation et évolution de la prise en charge thérapeutique à moyen terme des patients séropositifs pour le VIH-1 traités avec une combinaison antirétrovirale incluant Atazanavir
Sign or acronym	YZATIS
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL n°04-1334 (18/10/2004)
General Aspects	
Medical area	Infectious diseases
Others (details)	HIV
Keywords	care, Atazanavir
Scientific investigator(s) (Contact)	
Name of the director	Bennai
Surname	Yacia
Address	3, rue J. Monier - 92500 Rueil Malmaison
Phone	+33 (0)1 58 83 60 00
Email	yacia.bennai@bms.com
Unit	Bristol-Myers Squibb
Name of the director	Schmidely

Surname	Nathalie
Address	3, rue J. Monier - 92500 Rueil Malmaison
Phone	+33 (0)1 58 83 60 00
Email	nathalie.schmidely@bms.com
Unit	Bristol-Myers Squibb
Collaborations	
Funding	
Funding status	Private
Details	Bristol-Myers Squibb
Governance of the database	
Sponsor(s) or organisation(s) responsible	Bristol-Myers Squibb France (BMS)
Organisation status	Private
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Longitudinal study (except cohorts)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	random sampling in clusters
Database objective	
Main objective	Describe the arrangements for caring for patients treated by a combination of treatments including

ATAZANAVIR according to the grounds for introducing the treatment (virological failure of the previous treatment or other)

Inclusion criteria	M or F, aged 18 years or older, seropositive for HIV-1, treated via a combination of ARV treatments including ATV for which the main reason for introduction of the current treatment was: - virological failure of the previous treatment OR - another reason.
Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	National representativeness
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2004
Date of last collection (YYYY or MM/YYYY)	2006
Size of the database	
Size of the database (number of individuals)	[500-1000[individuals
Details of the number of individuals	626
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Declarative data Biological data

Clinical data (detail)	Direct physical measures Medical registration
Declarative data (detail)	Paper self-questionnaire
Biological data (detail)	cholesterol, TG, glycemia, bilirubin, liver enzymes, VL & CD4 (if available)
Presence of a biobank	No
Health parameters studied	Health event/morbidity Health care consumption and services Quality of life/health perception
Care consumption (detail)	Medicines consumption
Procedures	
Data collection method	Specific observation notebooks
Participant monitoring	Yes
Details on monitoring of participants	M3, M6, M12
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Terms of data access (charter for data provision, format of data, availability delay)	publication
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only